PHYSICIANS OFTEN PRESCRIBE COMBINATIONS of antibiotics because they feel they are widely effective, fairly harmless and prescribing combinations gives physicians a sense of security. This is true even at large medical centers. One report from Johns Hopkins Hospital notes that 11 percent of 7094 patients, admitted during a threemonth period, received from two to five antibiotics; only an additional 7 percent received a single antibiotic.
When antibiotics are administered in combination they produce effects as shown in the accompanying figure. 
HOURS AFTER INOCULATION
By far the most common result is indifference. Results of treatment are the same as could be obtained using a dose of one drug equivalent to the dose of the two drugs in the mixture. Antagonism between drugs is of clinical importance only in special situations such as in the treatment of bacterial meningitis where a mortality rate of 30 percent has been noted in pneumococcal meningitis treated with penicillin alone and, in contrast, 79 percent in patients receiving comparable doses of penicillin plus chlortetracycline. Unfortunately, combinations with synergistic action are rare, unpredictable and quite specific. A uniformly synergistic combination of antibiotics does not exist. A given combination must be tailored by laboratory tests to fit a specific organism isolated from a specific patient. The use of combinations of antimicrobial drugs has been reviewed and discussed by Jawetz who emphasizes that only in certain clinical conditions is combined therapy with antibiotics justified. 1 One clinical indication for combined therapy includes sepsis caused by gram-negative bacteria where it is imperative to begin treatment before the laboratory report identifying the specific etiologic organism is received. Among the combinations of possible use are streptomycin and chloramphenicol, kanamycin and chloramphenicol, kanamycin and ampicillin, kanamycin and polymyxin, streptomycin plus 
chloramphenicol plus penicillin, and many others depending on antibiotic sensitivity of the organisms in a specific hospital. Another use is in mixed infections, although the occasions are rare when a mixed flora requires a combination of drugs.
A third use of combinations is to delay the emergence of resistant strains of organisms and is the basis for the use of isoniazid, aminosalicylic acid and streptomycin in the treatment of tuberculosis. Again, sometimes the use of drugs in combination may reduce the incidence or intensity of adverse drug reactions. For example, if two drugs are each administered in one-half the usual concentration, this concentration may be below the level required to produce an adverse drug reaction. A strain of Pseudomonas may be inhibited ini vitro by polymyxin 5 µg/ml or by chloramphenicol 30 µg/ml used singly; or by a mixture of polymyxin 2 µg/ml plus chloramphenicol 15 µg/ml. The latter levels may be achieved by reasonably well-tolerated doses of each drug, whereas the dose to achieve the former may produce adverse effects.
At times, a combination of antibiotics will produce an effect not obtainable by either drug alone because the second drug enhances the activity of the first. Examples include the treatment of methicillin-resistant staphyloccal infections, of certain infections caused by gram-negative bacteria and the treatment of endocarditis caused by B-lactamase-producing staphylococci in pre-methicillin days.
Combined antibiotic therapy has many disadvantages. It engenders a false sense of security because of the implied promise of a "broad spectrum." It discourages efforts toward specific etiologic diagnosis, encourages inadequate dosage of drugs and harms the patient. Administration of a combination of antibiotics enhances the likelihood of adverse effects and increases their variety. It favors the emergence of microorganisms resistant to many drugs and thus contributes to the danger of hospital-borne infections.
Jawetz proposes a tentative scheme to serve as an experimental basis for combined antibiotic therapy. Antimicrobial drugs were divided into two groups: I. penicillins, streptomycin, neomycin-kanamycin, bacitracin, polymyxins; II. tetracyclines, chloramphenicol, erythromycins, novobiocin and sulfonamides. Synergism, manifested by enhancement of bactericidal activity in vitro, occurred most frequently among members of group I, and seldom among members of group II. The effect of a combination of group I and II drugs depended largely on the behavior of the organism toward the group I drug. If the organism were killed rapidly by the group I drug, addition of the group II drug might result in antagonism and slowing of the bactericidal rate. If the organism were relatively resistant to the group I drug, addition of a group II drug might produce synergism under some circumstances. This scheme is intended only as a framework for laboratory studies using a specific organism isolated from a specific patient.
Antibiotic combinations have a place, but they should not be prescribed indiscrimihately.
